BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV) rose 14.1% to $6.47, after the company disclosed that it has been approved for a grant from Israel's Ministry of Economy and Industry to build a facility for commercial scale production of its universal flu vaccine candidate M-001. Share volume was 2.4 million, towering over an all-day average of 39,000
